About Alchemi

Solving the R&D crisis

one report at a time

Why does it take over a decade and more than $1.5 billion to bring a drug to market?

Despite our knowledge of biology reaching new heights, technologies and processes have not kept pace.

Take bioanalysis. These assays are critical to drug development, yet the process for generating regulatory-compliant bioanalytical reports is horribly inefficient, creating costly delays for Sponsors and operational headaches for CROs. We founded Alchemi to change this.

We're a multidisciplinary team with expertise in drug development and computer science, united by a single mission: accelerate bioanalysis with the power of AI.

Tom Mulvey

CEO

Tom is the CEO and Co-founder of Alchemi. He started his career as a strategy consultant, and was investor at Vitruvian Partners, a leading private equity fund where he focused on partnering with CROs, CDMOs. Tom also spent time with CAR-T manufacturing pioneer Ori-Biotech, as well as gene-therapy developer Lexeo Therapeutics. Tom has an MBA from Harvard Business School.

Anuj Chadha

COO / CTO

Anuj is the COO / CTO and Co-founder of Alchemi. He studied at Caltech, focusing on Robotics / AI, and was a researcher at NASA's Jet Propulsion Lab. After this, he joined Vecna Robotics, a leading self-driving company, where he was a senior software engineer. Anuj has also spent time in venture capital with deep tech fund BlueYard Capital. Anuj has an MBA from Harvard Business School.

Solving the R&D crisis

one report at a time

Tom Mulvey

Anuj Chadha

Want to find out more?